20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1973 | PFI-4 | PFI4 | Epigenetic Reader Domain |
PFI-4 is a potent and selective and cell-permeable BRPF1 bromodomain inhibitor. | |||
T1850 | Balicatib | AAE581 | Cysteine Protease |
Balicatib (AAE581) is a potent and selective inhibitor of cathepsin K, used in trials studying the treatment of osteoporosis. | |||
T5751 | Tigogenin | Others | |
Tigogenin is one of steroidal sapogenins which is widely used for synthesizing steroid drugs. It might have protective effect on bone and be helpful in preventing the development of osteoporosis. | |||
T22702 | CYM 50769 | Neuropeptide W | |
CYM 50769 is a neuropeptide W/B receptor 1 (NPBWR1, GPR7) antagonist(IC50 = 0.12 μM). CYM 50769 inhibited NPW activation of NPBWR1 with a submicromolar IC50, and displayed high selectivity against a broad array of off-ta... | |||
T8550 | NDMC101 | Others , NF-κB , Proteasome | |
NDMC101 is an inhibitor of dipeptidyl peptidase-IV activity in human T cells and exhibits immunomodulatory effects. It also acts as a novel inhibitor of NFATc1 and NF-κB activity. | |||
T7469 | Alendronic Acid | alendronate | Others |
Alendronic Acid (alendronate) is a nonhormonal medication used for osteoporosis, osteogenesis imperfecta, and several other bone diseases. | |||
T5S2129 | Sciadopitysin | TNF , NF-κB | |
Sciadopitysin may prevent the development of diabetic osteopathy, it exerts its therapeutic effects via upregulation of mitochondrial biogenesis.Sciadopitysin shows protective effects on antimycin A-induced toxicity in o... | |||
T39508 | KY-02327 | Others | |
KY-02327, a metabolically stabilized analog of KY-02061, serves as a potent inhibitor of the Dishevelled (Dvl)-CXXC5 interaction. This compound activates the Wnt/β-catenin pathway, thereby promoting osteoblast differenti... | |||
T38776 | LP-922056 | Wnt/beta-catenin | |
LP-922056 is an inhibitor of Notum Pectinacetylesterase with EC50 values of 21 nM, 55 nM for human and mouse, respectively. | |||
T2121 | SW033291 | Dehydrogenase | |
SW033291 is a small-molecule inhibitor of 15-PGDH (Ki=0.1 nM) that increases prostaglandin PGE2 levels in bone marrow and other tissues. | |||
T5575 | Cycloastragenol | Cyclogalegenol,Astramembrangenin | Epigenetic Reader Domain , Telomerase |
Astramembrangenin (Cycloastragenol (Astramembrangenin)) is a triterpenoid saponin compound and a hydrolysis product of the main active ingredient in Astragalus membranaceus. Cycloastragenol (CAG) may have a novel therape... | |||
T21616 | L-006235 | L 006235 | Cysteine Protease |
L-006235 is a potent and reversible inhibitor of cathepsin K with IC50 of 0.25 nM. | |||
TN1494 | Cimicifugoside H-1 | Others | |
Cimicifugoside H1 shows the protective function to cerebral neuron during cerebral ischemia. | |||
T1867 | Otenaproxesul | ATB 346 | Apoptosis , COX |
Otenaproxesul (ATB 346) is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity. | |||
T8645 | PF-06446846 | Others | |
PF 06446846 is a potent and selective PCSK9 inhibitor | |||
T16159 | Muramyl dipeptide | MDP | NOD |
Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide indirectly decreases osteoclast differentiation... | |||
T6574 | Lumiracoxib | Prexige,COX-189 | COX |
Lumiracoxib (Prexige) is a novel, selective COX-2 inhibitor with IC50 and Ki of 0.14 μM and 0.06 μM, exhibits 515-fold selectivity over COX-1. Phase 4. | |||
T13324 | VUF11207 fumarate | CXCR , Arrestin | |
VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1). | |||
T2334 | Avanafil | TA1790 | PDE |
Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction. | |||
T4S0969 | Obtusifolin | Antioxidant , NF-κB | |
1. Obtusifolin has antioxidant properties and improves chemically induced diabetes and its complications by modulation of oxidative stress. 2. Obtusifolin suppresses phthalate esters-mediated bone resorption, thus may be... |